AmgenOne stock that hasn't benefitted from the S&P's 2013 climb is Amgen (AMGN - Get Report), the $64 billion pharmaceutical stock. Instead, Amgen has mostly churned sideways this year. But that could be about to change thanks to a bullish setup that's been forming in shares.
5 Big Stock Trades Signaling 'Buy'
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts